Zai Lab Reports Q1 2026 Earnings with Revenue Decline and R&D Growth
Zai Lab (NASDAQ: ZLAB) reported total product revenue of $99.6 million for the first quarter of 2026, a 6% year-over-year decline primarily due to lower sales from its drug ZEJULA. The company noted ongoing supply constraints affecting XACDURO and price reductions impacting VYVGART's performance.
Tickers: $ZLAB
Topics: clinical trial results pharmaceuticals R&D expenses revenue decline